Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Main Author: | Masatoshi Kudo |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-02-01
|
Series: | Liver Cancer |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/514312 |
Similar Items
-
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
by: Changhoon Yoo, et al.
Published: (2021-03-01) -
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Chi-Leung Chiang, et al.
Published: (2021-02-01) -
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01) -
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01) -
Second-line treatment of hepatocellular carcinoma: from theory to practical issues
by: V. V. Breder, et al.
Published: (2019-12-01)